CN-122005512-A - Method for improving quality of male sperms

Abstract

The application discloses a method for improving the quality of male sperms. Belongs to the technical field of biological medicine. The application discovers that the long-term administration of D-mannose in vivo can significantly improve the sperm quality of male mice. The main appearance is that the total movement rate and forward movement rate of the sperm are obviously increased, the effect is independent of the improvement of gonadal development, the mitochondrial membrane potential of the sperm is increased, the energy metabolism function is prompted to be improved, the integrity of the acrosome of the sperm is improved, and the sperm quality is integrally optimized. The result shows that the D-mannose as a safe natural monosaccharide can obviously improve the quality of male sperms through an in vivo intervention mode, and provides a new method and approach for the treatment and intervention of male infertility, especially asthenozoospermia.

Inventors

• LIU XUEYUAN
• ZHAO WENLONG

Assignees

• 杭州市妇产科医院

Dates

Publication Date

20260512

Application Date

20260319

Claims (7)

1. 1. A method for improving sperm quality in a male, comprising administering D-mannose in vivo.
2. 2. The method of claim 1, wherein the method of administration is oral or fed.
3. 3. The method of claim 1, wherein the amount applied is 6 to 18 g/kg/day.
4. Use of 4.D-mannose in the manufacture of a product for improving the quality of male sperm.
5. 5. The use according to claim 4, wherein the product is a pharmaceutical, nutraceutical or functional food.
6. 6. The use according to claim 4 for improving sperm motility, increasing mitochondrial membrane potential, and increasing acrosome integrity.
7. 7. The use of claim 6, wherein the sperm movement capacity comprises a total movement rate and a forward movement rate.

Description

Method for improving quality of male sperms Technical Field The invention relates to the technical field of biological medicine, in particular to a method for improving the quality of male sperms. Background Infertility has become a serious public health problem worldwide, with about half of the male factors. Asthenozoospermia (asthenozoospermia) is one of the most common types of male infertility, and is mainly manifested by reduced sperm motility, including insufficient forward motility, reduced total motility, and impaired sperm energy metabolism, ultimately resulting in reduced fertilization capacity. The causes of asthenozoospermia are complex, including genetic mutations, testicular dysfunction, endocrine imbalances, and environmental and lifestyle factors (e.g., smoking, drinking, obesity, drug or poison exposure, etc.). Due to multi-factor interlacing, the current clinical treatment effect is very limited. Current treatments for asthenospermia have limited options including gonadotrophin, clomiphene citrate, antioxidants and energy metabolism supplements (e.g. coenzyme Q10, l-carnitine, etc.). Although these drugs or supplements show some effects in some studies, the general problems of narrow application range, unstable curative effect, large side effects or lack of evidence-based medical evidence exist. There are also a number of health products on the market, which take "improving sperm quality" as a selling point, and common ingredients include vitamin C/E, zinc, selenium, coenzyme Q10 and L-carnitine. However, most studies have limited sample size and lack large-scale randomized controlled trials to confirm their efficacy, so clinical value is still unclear. In conclusion, no medicament or health care product at present lacks intervention means with clear mechanism, full evidence for evidence-based, truly effective, and obvious clinical demands and study blank still exist for male infertility, especially asthenozoospermia. D-mannose (D-mannose) is a natural monosaccharide, which is the C-2 epimer of glucose. Compared with glucose, D-mannose is metabolized in vivo in a different manner in that it does not enter mainly the glycolytic pathway after absorption through the digestive tract, but is partially utilized as a glycosylated substrate and is excreted in a larger proportion in the original form through urine. This unique metabolic feature makes it a distinct function from glucose in a number of medical and health fields. The most mature application of D-mannose is the prevention and adjuvant treatment of recurrent female urinary tract infections (urinary tract infection, UTI). The mechanism is that the escherichia coli FimH adhesin is competitively combined, and the bacteria are blocked from being combined with the urothelium, so that the bacteria are discharged along with urine. Several clinical studies have demonstrated that oral D-mannose can significantly reduce the incidence of recurrent UTI without causing resistance. US20040180839A1 proposes that a high concentration D-mannose environment is formed locally in the female genital tract, which can hinder the combination of the acrosome with the ovum, thereby exerting contraceptive effect. Embodiments include oral formulations, vaginal douches, contraceptive gels, and the like. Chinese patent CN110711198a reports that D-mannose can improve mouse depression-like behavior and reduce abnormal neurotransmitter levels in the brain, and thus is used for developing antidepressant drugs or health care products. Part of researches suggest that D-mannose possibly affects bone metabolism by participating in glycosylation and signal path regulation and control, and has application potential in osteoporosis prevention and treatment. International patent WO2009089442A1 proposes that D-mannose can assist in the treatment of metabolic diseases such as diabetes, insulin resistance and obesity by improving glucose tolerance, increasing insulin sensitivity. The above research directions are all directly connected with male reproduction. Therefore, research on the application of D-mannose in male fertility improvement is a technical problem to be solved urgently by those skilled in the art. Disclosure of Invention In view of this, the present invention provides a method for improving the quality of male sperm. The invention aims to provide a safe and effective in vivo intervention means, which improves the quality of male sperms by applying D-mannose, thereby improving fertility. The existing clinical medicines and health care intervention means have limited curative effects in the treatment of asthenozoospermia, often have the problems of narrow application range, unstable effect, large side effect or lack of evidence-based basis and the like, and can not meet the clinical requirements of male infertility. The invention discovers that D-mannose shows the effect of obviously improving the movement capacity, mitochondrial function and acrosome integrity of mal